National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Lumacaftor/ivacaftor (Orkambi®)

Orkambi® is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene.


Rapid Review

Commenced Completed Outcome
26/11/2015 15/12/2015 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
11/03/2016 01/06/2016 Reimbursement Not Recommended at the Submitted Price.

“The manufacturer Vertex Pharmaceuticals have confirmed that patients currently receiving Orkambi under the Managed Access Scheme will continue to receive the drug until reimbursement is finalised in Ireland”


The HSE has approved reimbursement following confidential price negotiations.